• 1

    Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 :97–106.

  • 2

    Kroeger A, Meyer R, Mancheno M, Gonzalez M, 1996. Health education for community-based malaria control: an intervention study in Ecuador, Colombia and Nicaragua. Trop Med Int Health 1 :836–846.

    • Search Google Scholar
    • Export Citation
  • 3

    Stowers A, Carter R, 2001. Current developments in malaria transmission-blocking vaccines. Expert Opin Biol Ther 1 :619–628.

  • 4

    Kocken CHM, Jansen J, Kaan AM, Beckers PJA, Ponnudurai T, Kaslow DC, Konings RNH, Schoerunakers JGG, 1993. Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum.Mol Biochem Parasitol 61 :59–68.

    • Search Google Scholar
    • Export Citation
  • 5

    Williamson KC, Fujioka H, Aikawa M, Kaslow DC, 1996. Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate. Mol Biochem Parasitol 78 :161–169.

    • Search Google Scholar
    • Export Citation
  • 6

    Tsuboi T, Tachibana M, Kaneko TO, Torii M, 2003. Transmission-blocking vaccine of P. vivax malaria. Parasitol Int 52 :1–11.

  • 7

    Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB, 1994. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum.Infect Immun 62 :5576–5580.

    • Search Google Scholar
    • Export Citation
  • 8

    Barr PJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC, 1991. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med 174 :1203–1208.

    • Search Google Scholar
    • Export Citation
  • 9

    Gozar MM, Price VL, Kaslow DC, 1998. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice. Infect Immun 66 :59–64.

    • Search Google Scholar
    • Export Citation
  • 10

    Williamson KC, Keister DB, Muratova O, Kaslow DC, 1995. Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes. Mol Biochem Parasitol 75 :33–42.

    • Search Google Scholar
    • Export Citation
  • 11

    Milek RL, Roeffen WF, Kocken CH, Jansen J, Kaan AM, Eling WM, Sauerwein RW, Konings RN, 1998. Immunological properties of recombinant proteins of the transmission blocking vaccine candidate, Pfs48/45, of the human malaria parasite Plasmodium falciparum produced in Escherichia coli.Parasite Immunol 20 :377–385.

    • Search Google Scholar
    • Export Citation
  • 12

    Hisaeda H, Collins WE, Saul A, Stowers AW, 2001. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism. Vaccine 20 :763–770.

    • Search Google Scholar
    • Export Citation
  • 13

    Hisaeda H, Stowers AW, Tsuboi T, Collins WE, Sattabongkot JS, Suwanabun N, Torii M, Kaslow DC, 2000. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun 68 :6618–6623.

    • Search Google Scholar
    • Export Citation
  • 14

    Arakawa T, Tsuboi T, Kishimoto A, Sattabongkot J, Suwanabun N, Rungruang T, Matsumoto Y, Tsuji N, Hisaeda H, Stowers A, Shimabukuro I, Sato Y, Torii M, 2003. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 21 :3143–3148.

    • Search Google Scholar
    • Export Citation
  • 15

    Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A, 2005. Phase I vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 :3131–3138.

    • Search Google Scholar
    • Export Citation
  • 16

    Salas ML, Romero JF, Solarte Y, Olano V, Herrera MA, Herrera S, 1994. Development of sporogonic cycle of Plasmodium vivax in experimentally infected Anopheles albimanus mosquitoes. Mem Inst Oswaldo Cruz 89 :115–119.

    • Search Google Scholar
    • Export Citation
  • 17

    Hurtado S, Salas ML, Romero JF, Zapata JC, Ortiz H, Arevalo-Herrera M, Herrera S, 1997. Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus.Ann Trop Med Parasitol 91 :49–60.

    • Search Google Scholar
    • Export Citation
  • 18

    Mu J, Duan J, Makova KD, Joy DA, Huynh CQ, Branch OH, Li WH, Su XZ, 2002. Chromosome-wide SNPs reveal an ancient origin for Plasmodium falciparum.Nature 418 :323–326.

    • Search Google Scholar
    • Export Citation
  • 19

    Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, Parise ME, Steketee RW, 2003. Malaria surveillance–United States, 2001. MMWR Surveill Summ 52 :1–14.

    • Search Google Scholar
    • Export Citation
  • 20

    Doberstyn EB, Teerakiartkamjorn C, Andre RG, Phintuyothin P, Noeypatimanondh S, 1979. Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. Trans R Soc Trop Med Hyg 73 :15–17.

    • Search Google Scholar
    • Export Citation
  • 21

    Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, Irving DO, Briggs WR, Mai A, Ginny M, Adiguma T, Rare L, Giddy A, Reber-Liske R, Stuerchler D, Alpers MP, 2000. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 18 :2504–2511.

    • Search Google Scholar
    • Export Citation
  • 22

    Saul A, Lawrence G, Smillie A, Rzepczyk CM, Reed C, Taylor D, Anderson K, Stowers A, Kemp R, Allworth A, Anders RF, Brown GV, Pye D, Schoofs P, Irving DO, Dyer SL, Woodrow GC, Briggs WR, Reber R, Sturchler D, 1999. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17 :3145–3159.

    • Search Google Scholar
    • Export Citation
  • 23

    Fries HCW, Lamers MBAC, van Deursen J, Ponnudurai T, Meuwissen JHET, 1990. Biosynthesis of the 25-kDa protein in the macrogametes/zygotes of Plasmodium falciparum.Exp Parasitol 71 :229–235.

    • Search Google Scholar
    • Export Citation
  • 24

    del Carmen Rodriguez M, Gerold P, Dessens J, Kurtenbach K, Schwartz RT, Sinden RE, Margos G, 2000. Characterisation and expression of pbs25, a sexual and sporogonic stage specific protein of Plasmodium berghei.Mol Biochem Parasitol 110 :147–159.

    • Search Google Scholar
    • Export Citation
  • 25

    Vermeulen AN, van Deursen J, Brakenhoff RH, Lensen TH, Ponnudurai T, Meuwissen JH, 1986. Characterization of Plasmodium falciparum sexual stage antigens and their biosynthesis in synchronised gametocyte cultures. Mol Biochem Parasitol 20 :155–163.

    • Search Google Scholar
    • Export Citation
  • 26

    Paton MG, Barker GC, Matsuoka H, Ramesar J, Janse CJ, Waters AP, Sinden RE, 1993. Structure and expression of a post-transcriptionally regulated malaria gene encoding a surface protein from the sexual stages of Plasmodium berghei.Mol Biochem Parasitol 59 :263–275.

    • Search Google Scholar
    • Export Citation
Past two years Past Year Past 30 Days
Abstract Views 2 2 2
Full Text Views 359 127 2
PDF Downloads 103 41 1
 
 
 
 
 
 
 
 
 
 
 

INDUCTION OF TRANSMISSION-BLOCKING IMMUNITY IN AOTUS MONKEYS BY VACCINATION WITH A PLASMODIUM VIVAX CLINICAL GRADE PVS25 RECOMBINANT PROTEIN

MYRIAM ARÉVALO-HERRERAInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by MYRIAM ARÉVALO-HERRERA in
Current site
Google Scholar
PubMed
Close
,
YEZID SOLARTEInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by YEZID SOLARTE in
Current site
Google Scholar
PubMed
Close
,
MARÍA FERNANDA YASNOTInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by MARÍA FERNANDA YASNOT in
Current site
Google Scholar
PubMed
Close
,
ANGÉLICA CASTELLANOSInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by ANGÉLICA CASTELLANOS in
Current site
Google Scholar
PubMed
Close
,
ADRIANA RINCÓNInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by ADRIANA RINCÓN in
Current site
Google Scholar
PubMed
Close
,
ALLAN SAULInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by ALLAN SAUL in
Current site
Google Scholar
PubMed
Close
,
JIANBING MUInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by JIANBING MU in
Current site
Google Scholar
PubMed
Close
,
CAROLE LONGInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by CAROLE LONG in
Current site
Google Scholar
PubMed
Close
,
LOUIS MILLERInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by LOUIS MILLER in
Current site
Google Scholar
PubMed
Close
, and
SÓCRATES HERRERAInstituto de Inmunología del Valle, Universidad del Valle, Cali, Colombia; Malaria Vaccine and Drug Development Center, Cali, Colombia; Malaria Vaccine Development Branch and Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Search for other papers by SÓCRATES HERRERA in
Current site
Google Scholar
PubMed
Close
View More View Less
Restricted access

Aotus monkeys were used to determine the immunogenicity of Pvs25 protein expressed in the zygote/ookinete surface. Animals were immunized in three times with 100 μg of Pvs25 formulated in Montanide ISA-720. Antibodies to Pvs25 detected by an enzyme-linked immunosorbent assay appeared by day 30 after the first immunization, with a peak of antibodies levels on day 150. These antibodies were still detectable on day 300. Plasma samples on day 150 from experimental group were able to completely block the development of the parasite in Anopheles albimanus mosquitoes artificially fed with human isolates of Plasmodium vivax. Immunized Aotus monkeys were infected with blood forms of the P. vivax Salvador I strain and no boosting effect of blood infection on titers of antibodies to Pvs25 was observed despite the presence of infective gametocytes. In conclusion, Pvs25 protein formulated in Montanide ISA-720 induces efficient and long-lasting transmission-blocking antibodies that cannot be boosted by parasite infection.

Save